2-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)ethanone | 726140-60-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 2-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)ethanone
• 英文别名: 2-chloro-1-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)ethanone
• CAS: 726140-60-9
• 化学式: C₁₆H₁₃Cl₂NO
• 分子量: 306.191
• InChiKey: ZFHSLBSLCKVSSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)ethanone 在 硼烷四氢呋喃络合物 、 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.5h， 生成 methyl (3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)carbamate
  参考文献：
  名称：

  Reengineered tricyclic anti-cancer agents

  摘要：

  The phenothiazine and dibenzazepine tricyclics are potent neurotropic drugs with a documented but underutilized anti-cancer side effect. Reengineering these agents (TFP, CPZ, CIP) by replacing the basic amine with a neutral polar functional group (e.g., RTC-1, RTC-2) abrogated their CNS effects as demonstrated by in vitro pharmacological assays and in vivo behavioral models. Further optimization generated several phenothiazines and dibenzazepines with improved anti-cancer potency, exemplified by RTC-5. This new lead demonstrated efficacy against a xenograft model of an EGFR driven cancer without the neurotropic effects exhibited by the parent molecules. Its effects were attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.07.007
• 作为产物：
  描述：

  3-氯亚氨基二苄 、 氯乙酰氯 以 甲苯 为溶剂， 反应 12.0h， 以53%的产率得到2-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)ethanone
  参考文献：
  名称：

  新型γ-氨基丁酸（GABA）摄取抑制剂的合成。5.（1）已知GABA吸收抑制剂的三环类似物的制备和结构活性研究。

  摘要：

  基于一系列已知的γ-氨基丁酸（GABA）摄取抑制剂（包括4种（SKF 89976））的SAR，已制备了新的三环类似物。这些新颖的化合物是乳香酸，番石榴碱和高β-脯氨酸的衍生物，在这些氨基酸的氮上被各种亲脂性部分所取代，例如（10,11-dihydro-5H-dibenz [b，f] azepin-5 -基）烷氧基烷基或（10,11-二氢-5H-二苯并[a，d]环庚基-5-亚烷基）烷氧基烷基。确定了该新系列中每种化合物抑制大鼠突触小体中[（3）H] -GABA吸收的体外值，并且发现几种新型化合物显示出与参考化合物相当的高效价4、5（替加滨）和6（CI-966）。还评估了几种新型化合物的体内抑制15 mg / kg（ip）剂量的6,7-二甲氧基-4-乙基-β-咔啉-3-羧酸甲酯（DMCM）诱发的阵挛性癫痫发作的能力。 。一种化合物是（R）-1-（2-（2-（2-（10,11-二氢-5H-二苯并[b，f]

  DOI：

  10.1021/jm990513k

文献信息

• [EN] TRICYCLIC MODULATORS OF PP2A<br/>[FR] MODULATEURS TRICYCLIQUES DE PP2A
  申请人：RAPPTA THERAPEUTICS OY

  公开号：WO2021170913A1

  公开（公告）日：2021-09-02

  Chemical modulators of PP2A, comprising tricyclic sulfonimidamides are disclosed. The compounds are useful in preventing or treating cancer, diabetes, autoimmune disease, solid organ transplant rejection, graft vs host disease, chronic obstructive pulmonary disease (COPD), non-alcoholic fatty liver disease, abdominal aortic aneurysm, chronic liver disease, heart failure, neurodegenerative disease and cardiac hypertrophy. The compounds are of formula (I)

  化学调节剂PP2A，包括三环磺胺亚胺类化合物。这些化合物对预防或治疗癌症、糖尿病、自身免疫疾病、固体器官移植排斥、移植物抗宿主病、慢性阻塞性肺疾病（COPD）、非酒精性脂肪肝病、腹主动脉瘤、慢性肝病、心力衰竭、神经退行性疾病和心肌肥大具有用处。这些化合物的化学式为（I）。
• TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS
  申请人：Ohlmeyer Michael

  公开号：US20140213578A1

  公开（公告）日：2014-07-31

  Tricyclic chemical modulators of FOXO transcription factor proteins are disclosed. The compounds are useful to treat cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne. The compounds are of the following phenothiazine, dibenzoazepine and annulene and similar genera:

  本文披露了三环化学调节剂对FOXO转录因子蛋白的调节作用。这些化合物可用于治疗癌症、年龄相关蛋白质毒性、压力引起的抑郁症、炎症和痤疮。这些化合物属于以下苯硫噻嗪、二苯并氮杂环和环戊烯类似物系列：
• Discovery and Mechanism Study of SARS-CoV-2 3C-like Protease Inhibitors with a New Reactive Group
  作者：Pengxuan Ren、Hui Li、Tianqing Nie、Xiaoqin Jian、Changyue Yu、Jian Li、Haixia Su、Xianglei Zhang、Shiwei Li、Xin Yang、Chao Peng、Yue Yin、Leike Zhang、Yechun Xu、Hong Liu、Fang Bai

  DOI：10.1021/acs.jmedchem.3c00818

  日期：2023.9.14

  we identified a potent inhibitor of 3CLpro (3a) that contains a thiocyanate moiety as a novel warhead that can form a covalent bond with Cys145 of the protein. Tandem mass spectrometry (MS/MS) and X-ray crystallography confirmed the mechanism of covalent formation between 3a and the protein in its catalytic pocket. Moreover, several analogues of compound 3a were designed and synthesized. Among them

  3CL pro是治疗 COVID-19 的一个有吸引力的靶点。使用支架跳跃策略，我们鉴定了 3CL pro ( 3a )的有效抑制剂，其含有硫氰酸盐部分作为新型弹头，可以与蛋白质的 Cys145 形成共价键。串联质谱 (MS/MS) 和 X 射线晶体学证实了3a与其催化口袋中的蛋白质之间形成共价键的机制。此外，还设计并合成了化合物3a的几种类似物。其中，化合物3h对3CL pro的抑制效果最好，IC 50为0.322 μM，k inact / K i值为1669.34 M –1 s –1，并且对3CL pro对宿主蛋白酶表现出良好的靶点选择性。化合物3c可抑制 Vero E6 细胞中的 SARS-CoV-2 (EC 50 = 2.499 μM)，且细胞毒性较低 (CC 50 > 200 μM)。这些研究为未来探索和开发新的 3CL前体抑制剂提供了思路和见解。
• [EN] TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS<br/>[FR] COMPOSÉS TRICYCLIQUES EN TANT QU'AGENTS ANTICANCÉREUX
  申请人：MT SINAI SCHOOL OF MEDICINE

  公开号：WO2013025882A3

  公开（公告）日：2013-04-25
• N-Homolupinanoyl and N-(ω-lupinylthio)alkanoyl derivatives of some tricyclic systems as ligands for muscarinic M1 and M2 receptor subtypes
  作者：Bruno Tasso、Anna Sparatore、Fabio Sparatore

  DOI：10.1016/s0014-827x(03)00104-6

  日期：2003.9

  A set of N-homolupinanoyl- and N-(omega-lupinylthio)alkanoyl derivatives of tricyclic systems (as phenothiazine, iminodibenzyl and dihydropyridobenzodiazepinone) has been prepared and tested for affinity for rat muscarinic M(1) and M(2) receptor subtypes labeled with [3H]pirenzepine and [3H]AF-DX 384. Good affinity for both M(1) and M(2) subtypes was displayed by most compounds, often with nanomolar K(i) values, which for lupinylthiopropionyl- and lupinylthiobutyryl-phenothiazines (13-16) were comparable to those of pirenzepine and methoctramine, respectively. However, only moderate selectivity for one or the other subtype was seen.